Cancer clinical trials in the region Centre-Val de Loire

111 currently recruiting clinical trials
Region Centre-Val de Loire

Phase 3 Prostate cancer #NCT06952803 #2024-513586-39-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Biochemical recurrence
Required genetic anomalies
BRCA 1/2
Required previous treatments at localized stage
Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Targeted therapy
20 recruiting sites
AstraZeneca
Phase 3 Lung cancer #NCT06417814 #2024-511362-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy
14 recruiting sites
AstraZeneca
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06973187 #2025-522860-34-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
BeOne Medecines
Phase 3 Lymphoma #NCT06742996 #2024-515593-27-00
Required histologic types
B cell lymphoma
Required histologic sub types
Mantel cell lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive
2 recruiting sites
BeOne Medecines
Phase 3 Lung cancer #NCT06908993 #2024-519971-25-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded genetic anomalies
ALK BRAF EGFR HER2 KRAS non G12C RET ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
32 recruiting sites
Intergroupe Francophone de Cancérologie Thoracique
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06428019 #2024-512147-23-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Abbvie
Phase 3 Prostate cancer #NCT04916613 #2022-502425-18-00
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
49 recruiting sites
UNICANCER
Phase 3 Kidney cancer #NCT06364631 #2023-503317-29-00
Required histologic types
Clear cell carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required IMDC scores
0 1 or 2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
36 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Breast cancer #NCT05232916 #2023-504323-25-01
Required HER2 statuses
HER2 Positive
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
22 recruiting sites
Greenwich LifeSciences, Inc.
Phase 3 Lung cancer #NCT05692999 #2023-503481-23-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
28 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris